dude, BPSR
Do you realize that with 750M shares, even if fully diluted, the company would have to make net income of $7.5M/qtr to even post $.01/qtr EPS. So this new drug, which is only in phase 1/2 would have to make them at least $30M/year net income in order to post $.04 EPS. In the meantime, shareholder equity is in deficit, and who knows when or if this drug ever gets to market. Very risky play IMO, even though they got an IND from the FDA. I mean stock up from $.04 to $.32 in a month( or so because of the IND and a few positive patient results ? Maybe it runs more, but is surely could get cut in half or more real fast too.
